Kezar Life Sciences Inc. (NASDAQ:KZR) and Theravance Biopharma Inc. (NASDAQ:TBPH) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kezar Life Sciences Inc.	N/A	0.00	23.17M	-1.05	0.00
Theravance Biopharma Inc.	60.37M	21.19	215.52M	-4.72	0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Kezar Life Sciences Inc. and Theravance Biopharma Inc.

Profitability

Table 2 has Kezar Life Sciences Inc. and Theravance Biopharma Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Kezar Life Sciences Inc.	0.00%	0%	0%
Theravance Biopharma Inc.	-357.00%	-520.6%	-60.6%

Liquidity

32.9 and 32.9 are the respective Current Ratio and a Quick Ratio of Kezar Life Sciences Inc. Its rival Theravance Biopharma Inc.’s Current and Quick Ratios are 3.3 and 3.1 respectively. Kezar Life Sciences Inc. has a better chance of clearing its pay short and long-term debts than Theravance Biopharma Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Kezar Life Sciences Inc. and Theravance Biopharma Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Kezar Life Sciences Inc.	0	0	0	0.00
Theravance Biopharma Inc.	0	0	2	3.00

Theravance Biopharma Inc. on the other hand boasts of a $47.5 average target price and a 108.33% potential upside.

Insider and Institutional Ownership

Kezar Life Sciences Inc. and Theravance Biopharma Inc. has shares owned by institutional investors as follows: 49.1% and 87.4%. About 12.65% of Kezar Life Sciences Inc.’s share are owned by insiders. Insiders Competitively, owned 5.7% of Theravance Biopharma Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Kezar Life Sciences Inc.	-0.34%	13.07%	-20.02%	17.87%	0%	-14.19%
Theravance Biopharma Inc.	-0.37%	-6.1%	-8.46%	-14.12%	-7.96%	-4.42%

For the past year Kezar Life Sciences Inc.’s stock price has bigger decline than Theravance Biopharma Inc.

Summary

Kezar Life Sciences Inc. beats on 6 of the 10 factors Theravance Biopharma Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The companyÂ’s product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.